Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 876

1.

Bortezomib in the front-line treatment of multiple myeloma.

Richardson PG, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, Munshi N, Anderson KC.

Expert Rev Anticancer Ther. 2008 Jul;8(7):1053-72. doi: 10.1586/14737140.8.7.1053. Review.

PMID:
18588451
2.

Treatment of multiple myeloma: 2009 update.

[No authors listed]

Prescrire Int. 2009 Dec;18(104):263-6.

PMID:
20025098
3.

"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.

Gasparetto C, Gockerman JP, Diehl LF, de Castro CM, Moore JO, Long GD, Horwitz ME, Keogh G, Chute JP, Sullivan KM, Neuwirth R, Davis PH, Sutton LM, Anderson RD, Chao NJ, Rizzieri D.

Biol Blood Marrow Transplant. 2010 Jan;16(1):70-7. doi: 10.1016/j.bbmt.2009.08.017. Epub 2009 Sep 3.

4.

Management of multiple myeloma with bortezomib: experts review the data and debate the issues.

Dicato M, Boccadoro M, Cavenagh J, Harousseau JL, Ludwig H, San Miguel J, Sonneveld P.

Oncology. 2006;70(6):474-82. Epub 2007 Feb 2. Review.

PMID:
17283449
5.

The emerging role of novel therapies for the treatment of relapsed myeloma.

Richardson PG, Hideshima T, Mitsiades C, Anderson KC.

J Natl Compr Canc Netw. 2007 Feb;5(2):149-62. Review.

PMID:
17335684
6.

Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.

Kim HJ, Yoon SS, Lee DS, Sohn SK, Eom HS, Lee JL, Chung JS, Kim K, Suh C, Won JH, Kim JS, Park JS, Kang HJ, Seong CM, Kim CS, Lee SJ, Lee JH.

Ann Hematol. 2012 Feb;91(2):249-56. doi: 10.1007/s00277-011-1298-9. Epub 2011 Jul 26.

PMID:
21789621
7.

Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.

Palumbo A, Attal M, Roussel M.

Clin Cancer Res. 2011 Mar 15;17(6):1253-63. doi: 10.1158/1078-0432.CCR-10-1925. Review.

8.

Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma.

Lonial S, Cavenagh J.

Br J Haematol. 2009 Jun;145(6):681-708. doi: 10.1111/j.1365-2141.2009.07649.x. Epub 2009 Mar 17. Review.

PMID:
19344388
9.

New drugs for myeloma.

Richardson PG, Mitsiades C, Schlossman R, Munshi N, Anderson K.

Oncologist. 2007 Jun;12(6):664-89. Review.

10.

Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.

Eom HS, Min CK, Cho BS, Lee S, Lee JW, Min WS, Kim CC, Kim M, Kim Y.

Jpn J Clin Oncol. 2009 Jul;39(7):449-55. doi: 10.1093/jjco/hyp046. Epub 2009 Jun 1.

PMID:
19487425
11.

Advances in therapy of multiple myeloma.

Bladé J, Rosiñol L.

Curr Opin Oncol. 2008 Nov;20(6):697-704. doi: 10.1097/CCO.0b013e3283136984. Review.

PMID:
18841053
12.

Clinical impact of bortezomib in frontline regimens for patients with multiple myeloma.

Manochakian R, Miller KC, Chanan-Khan AA.

Oncologist. 2007 Aug;12(8):978-90. Review.

13.

Treatment of multiple myeloma in the targeted therapy era.

Saad AA, Sharma M, Higa GM.

Ann Pharmacother. 2009 Feb;43(2):329-38. doi: 10.1345/aph.1L428. Epub 2009 Feb 3. Review.

PMID:
19193585
14.

Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.

Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP, Heyman M, Akpek G, Fenton RG.

Cancer. 2007 Sep 1;110(5):1042-9. Review.

15.

Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.

Bladé J, Cibeira MT, Rosiñol L.

Acta Oncol. 2005;44(5):440-8. Review.

PMID:
16118077
16.

Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.

Palumbo A, Gay F, Falco P, Crippa C, Montefusco V, Patriarca F, Rossini F, Caltagirone S, Benevolo G, Pescosta N, Guglielmelli T, Bringhen S, Offidani M, Giuliani N, Petrucci MT, Musto P, Liberati AM, Rossi G, Corradini P, Boccadoro M.

J Clin Oncol. 2010 Feb 10;28(5):800-7. doi: 10.1200/JCO.2009.22.7561. Epub 2010 Jan 4. Erratum in: J Clin Oncol. 2010 May 1;28(13):2314.

PMID:
20048187
17.

Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP).

Eom HS, Kim YK, Chung JS, Kim K, Kim HJ, Kim HY, Jin JY, Do YR, Oh SJ, Suh C, Seong CM, Kim CS, Lee DS, Lee JH.

Ann Hematol. 2010 May;89(5):489-97. doi: 10.1007/s00277-009-0871-y. Epub 2009 Dec 10.

PMID:
20012045
18.

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study.

Mateos MV, Hernández JM, Hernández MT, Gutiérrez NC, Palomera L, Fuertes M, Díaz-Mediavilla J, Lahuerta JJ, de la Rubia J, Terol MJ, Sureda A, Bargay J, Ribas P, de Arriba F, Alegre A, Oriol A, Carrera D, García-Laraña J, García-Sanz R, Bladé J, Prósper F, Mateo G, Esseltine DL, van de Velde H, San Miguel JF.

Blood. 2006 Oct 1;108(7):2165-72. Epub 2006 Jun 13.

19.

Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma.

Vogl DT, Stadtmauer EA, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Facon T, Harousseau JL, Boral A, Neuwirth R, Anderson KC.

Br J Haematol. 2009 Nov;147(4):531-4. doi: 10.1111/j.1365-2141.2009.07875.x. Epub 2009 Sep 1.

PMID:
19725827
20.

(Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.

Wang A, Duan Q, Liu X, Ding K, Han Y, Zhu W, Cai X, Wu J, Sun Z.

Ann Hematol. 2012 Nov;91(11):1779-84. doi: 10.1007/s00277-012-1520-4. Epub 2012 Jul 7.

PMID:
22773209

Supplemental Content

Support Center